Data from a large, randomized clinical trial named SELECT indicate cardiovascular protective benefits from taking the GLP-1 weight loss therapeutic Wegovy (semaglutide) for a sub-population with preexisting cardiovascular disease
In the world of pharmaceuticals and life sciences, Cold chain solutions shouldnt come at the cost of the environment
Not eligible for SilverSneakers
This compound, known as exenatide, mimics the effects of GLP-1, a hormone that plays a critical role in appetite suppression, insulin secretion and glucose metabolism
This provides a theoretical basis for uncertainty management, serving as a crucial caveat for clinicians: when utilizing GLP-1RAs, one must distinguish between the relative certainty of metabolic benefits and the stochastic nature of reproductive improvements
The compound has a half-life of approximately six days, which allows for convenient once-weekly dosing